DMF treatment ameliorates the disease course of experimental autoimmune encephalomyelitis (EAE) and exerts neuroprotective effects by activating the anti-oxidant nuclear factor erythroid 2 related factor 2 (Nrf2) pathway (13). Here, NFE2L2 is linked to experimental autoimmune encephalomyelitis.